PCI Biotech Holding ASA (PCIB)

Oslo
Currency in NOK
1.30
+0.03(+2.35%)
Closed·
PCIB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.301.33
52 wk Range
1.103.50
Key Statistics
Edit
Prev. Close
1.27
Open
1.33
Day's Range
1.3-1.33
52 wk Range
1.1-3.5
Volume
903
Average Vol. (3m)
72.66K
1-Year Change
-23.53%
Book Value / Share
0.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PCIB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile
Show more

PCI Biotech Holding ASA Company Profile

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

PCI Biotech Holding ASA Earnings Call Summary for Q4/2024

  • Q4 2024 earnings call lacked clear financial data and strategic insights, leading to a 2.5% stock dip in pre-market trading
  • Revenue of $0.56 million reported for last twelve months, with 115% revenue growth, according to InvestingPro data
  • Stock currently trading at $0.14, between 52-week range of $0.10 to $0.31, with 29% return over past week and 35% year-to-date gain
  • No clear forward-looking guidance or strategic initiatives outlined, raising investor uncertainty about future performance
  • Vague references to partnerships and public grants suggest potential operational challenges and unclear product development progress
Last Updated: 02/27/2025, 03:19 AM
Read Full Transcript

Compare PCIB to Peers and Sector

Metrics to compare
PCIB
Peers
Sector
Relationship
P/E Ratio
−3.0x0.0x−0.5x
PEG Ratio
−0.150.000.00
Price / Book
2.1x0.0x2.6x
Price / LTM Sales
7.2x0.0x2.9x
Upside (Analyst Target)
-0.0%66.0%
Fair Value Upside
Unlock0.0%10.6%Unlock

Earnings

Latest Release
Feb 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the PCI Biotech (PCIB) Stock Price Today?

The PCI Biotech stock price today is 1.30

What Stock Exchange Does PCI Biotech Trade On?

PCI Biotech is listed and trades on the Oslo stock exchange.

What Is the Stock Symbol for PCI Biotech?

The stock symbol for PCI Biotech is "PCIB."

What Is the PCI Biotech Market Cap?

As of today, PCI Biotech market cap is 48.52M.

What is PCI Biotech Earnings Per Share?

The PCI Biotech EPS is -0.44.

What Is the Next PCI Biotech Earnings Date?

PCI Biotech will release its next earnings report on May 07, 2025.

From a Technical Analysis Perspective, Is PCIB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.